e-Drug3D

2044

ATOGEPANT

INN
ATOGEPANT

cas 1374248-81-3

CLASS

NERVOUS SYSTEM
TREATMENT OF EPISODIC MIGRAINE
CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST (CGRP)

ROUTE (list)

ORAL

ATC code

N02CD07

PK parameters

Tmax 1.5 HOUR
VD 292 LITER
Cl 19 LITER / HOUR
PPB 95.3 PERCENT
t1/2 11 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET CALCITONIN GENE-RELATED PEPTIDE RECEPTOR

DrugCentral

Calcitonin gene-related peptide type 1 receptor UNIPROT Q16602

Download SDF file

Spiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1',2',5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl]-2'-oxo-, (3'S)- (ACI)

Formula:
C29H23F6N5O3

Calculated chemical properties:

MW 603.52
NB_atoms 43
XLogP 3.95
PSA 95.043
NB_HD 2
NB_HA 8
fsp3 0.34
Lipinski(0=no;1=yes) 0

FDA
NDA 215206 (pdf not found) INN (ATOGEPANT) QULIPTA (ABBVIE) APPROVAL= AP YEAR= 2021